share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股sec公告 ·  07/29 16:11
Moomoo AI 已提取核心信息
TC BioPharm (Holdings) plc successfully conducted its 2024 Annual General Meeting (AGM) on July 24, 2024, with all proposed resolutions passed. The AGM saw the approval of the company's annual report and audited financial statements for the year ended December 31, 2023. Shareholders also approved the Directors' Remuneration Report for the same period. Marcum LLP was ratified as the U.S. independent registered public accounting firm for the upcoming year, while Ecovis was re-appointed as the U.K. statutory auditor until the next AGM. Additionally, the Audit Committee was authorized to determine the remuneration of the U.K. statutory auditor for the year ending December 31, 2024. A provision to adjourn the AGM to a later date if necessary was also approved. The full text of each resolution was included in the Notice of Annual General Meeting distributed to shareholders on July 1, 2024, and filed with the U.S. Securities and Exchange Commission.
TC BioPharm (Holdings) plc successfully conducted its 2024 Annual General Meeting (AGM) on July 24, 2024, with all proposed resolutions passed. The AGM saw the approval of the company's annual report and audited financial statements for the year ended December 31, 2023. Shareholders also approved the Directors' Remuneration Report for the same period. Marcum LLP was ratified as the U.S. independent registered public accounting firm for the upcoming year, while Ecovis was re-appointed as the U.K. statutory auditor until the next AGM. Additionally, the Audit Committee was authorized to determine the remuneration of the U.K. statutory auditor for the year ending December 31, 2024. A provision to adjourn the AGM to a later date if necessary was also approved. The full text of each resolution was included in the Notice of Annual General Meeting distributed to shareholders on July 1, 2024, and filed with the U.S. Securities and Exchange Commission.
TC生物医药（控股）股份有限公司已于2024年7月24日成功举行2024年度股东大会（AGM），并通过了所有建议的决议。AGM通过了公司截至2023年12月31日的年度报告和审计财务报表的批准。股东们还批准了该期间的董事报酬报告。Marcum LLP被批准为即将到来的一年美国独立注册公共会计师事务所，而Ecovis被重新任命为英国法定审计师，直至下一届股东大会。此外，审计委员会被授权判断截至2024年12月31日的英国法定审计师报酬。如果需要，还批准将AGM延期至以后的日期。每项决议的全文都包含在2024年7月1日向股东分发的年度股东大会通知书中，并向美国证券交易委员会报告。
TC生物医药（控股）股份有限公司已于2024年7月24日成功举行2024年度股东大会（AGM），并通过了所有建议的决议。AGM通过了公司截至2023年12月31日的年度报告和审计财务报表的批准。股东们还批准了该期间的董事报酬报告。Marcum LLP被批准为即将到来的一年美国独立注册公共会计师事务所，而Ecovis被重新任命为英国法定审计师，直至下一届股东大会。此外，审计委员会被授权判断截至2024年12月31日的英国法定审计师报酬。如果需要，还批准将AGM延期至以后的日期。每项决议的全文都包含在2024年7月1日向股东分发的年度股东大会通知书中，并向美国证券交易委员会报告。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息